Delivery Order SPE2DB22D3004-SPE2DB25FQ73S
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,483.62 to AmerisourceBergen Drug Corp for RYTARY ER 23.75 mg-95 mg capsules (100-count units) on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitively awarded transaction. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency awarded a delivery order valued at $44,283.84 to AmerisourceBergen Drug Corp for the supply of RYTARY ER (extended-release carbidopa-levodopa) 36.25 mg-145 mg capsules in a quantity of 100 units. The contract is a firm fixed price delivery order with an ultimate completion date of June 9, 2025, and was awarded on June 6, 2025 without any set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,906.55 to AmerisourceBergen Drug Corp for RYTARY ER 36.25 mg-145 mg capsules (100-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of April 24, 2025, and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA. The product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- This delivery order, awarded August 28, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides for the supply of RYTARY ER (extended-release carbidopa-levodopa) 36.25 mg-145 mg capsules in quantities of 100 units. The contract carries a ceiling value of $10,351.48 and represents a firm fixed-price delivery order with an ultimate completion date of August 29, 2025. The award was competitively procured without set-aside designation and is being performed at...
- The Defense Logistics Agency awarded a $3,565.50 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of RYTARY ER (extended-release carbidopa-levodopa) 36.25 mg-145 mg capsules in a quantity of 100 units. The delivery order is issued under a firm fixed-price contract with an ultimate completion date of July 21, 2025, and will be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This award includes no set-aside designation and was awarded...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,935.59 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 48.75 MG-195 MG capsules (100-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,910.55 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg-195 mg capsules (100-count), a Parkinson's disease medication. This firm fixed-price delivery order, issued on September 16, 2025, with an ultimate completion date of September 17, 2025, was awarded competitively without a set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award...
- The Defense Logistics Agency awarded a $10,505.12 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of RYTARY ER 36.25 mg-145 mg capsules (100-count units). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of July 15, 2025, performed at the contractor's facility in Conshohocken, Pennsylvania. RYTARY ER is a sustained-release formulation of levodopa-carbidopa used in Parkinson's disease treatment, reflecting the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $2,102.87 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg–195 mg capsules (100 count) on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,826.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RYTARY ER (extended-release carbidopa/levodopa) 36.25 mg-145 mg capsules, 100-count bottles. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 8, 2025. AmerisourceBergen will fulfill this pharmaceutical supply requirement from its corporate office location in Conshohocken, Pennsylvania, where the company serves as a...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FQ73SDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,013.49 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 36.25 MG-145 MG capsules (100-count) under a firm fixed-price contract. The award was made on September 15, 2025, with an ultimate completion date of September 16, 2025, and does not include a set-aside designation. Performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, fulfills a significant role in supporting military and veteran healthcare systems through the DLA Medical Supply Chain. The SPE2DX contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and other medical commodities across multiple therapeutic domains. RYTARY ER, a long-acting formulation of carbidopa/levodopa used in Parkinson's disease management, represents one of many specialized pharmaceutical products delivered under this contract framework to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.0k | 9/15/25 |